The story of Viagra presents a nuanced case for observers in the pharmaceutical sector. While initially a phenomenal success, generating vast sums, the exclusivity expiration and the subsequent entry of generic versions have drastically impacted earnings. This poses questions about the future sustainability of similar medication innovations and … Read More